miR-205-5p靶向调控HMGB1/TLR4通路对变应性鼻炎及其免疫功能的作用和机制 研究; 项目编号：2021JJ70079
1.Hunan Children'2.'3.s Hospital
目的：研究微小RNA-205-5p（Microrna-205-5p，miR-205-5p）靶向高迁移率族蛋白B1/Toll样受体4（High mobility group protein B1 / toll like receptor 4，HMGB1/TLR4）途径改善变应性鼻炎（Anaphylactic rhinitis，AR）免疫功能的作用。方法：选取60只雄性大鼠，分为正常对照组（A组）、变应性鼻炎组（B组）、变应性鼻炎+miR-205-5p agomir组（C组）、变应性鼻炎+miR-205-5p antagomir组（D组）4组，每组15只，A组不做任何处理，B、C、D组均采用卵清白蛋白鼻腔强化致敏建立AR模型。模型建立完成后，C组尾部注射300 μg miR-205-5p agomir，D组尾部注射miR-205-5p antagomir，A、B组均注射生理盐水。1周后评价各组行为学、免疫相关指标[干扰素-γ（IFN-γ）、白介素-2（IL-2）、白介素-4（IL-4）、白介素-10（IL-10）、免疫球蛋白E（IgE）]、鼻黏膜炎性反应、上皮细胞间紧密连接、内质网形态及紧密连接蛋白、HMGB1/TLR4途径蛋白表达量。miR-205-5p与TLR4的靶向关系使用双荧光素酶报告实验分析。结果：各个组别行为学评分、IL-4、IgE、HMGB1、TLR4、NF-κB表达量、紧密连接宽度自低至高分别为A组＜B组＜C组＜D组；IFN-γ、IL-2、IL-10、紧密连接蛋白表达量自低至高分别为D组＜C组＜B组＜A组，且各组之间对比，差异具有统计学意义（均P＜0.05）。双荧光素酶报告结果表明miR-205-5p可与TLR4靶向结合。结论：miR-205-5p可靶向HMGB1/TLR4途径抑制Th1/Th2失衡所引起的AR免疫障碍，加强鼻黏膜屏障功能，从而减少变应原的入侵，缓解AR相关症状，对AR的治疗产生积极作用。
Objective: To study the effect of microrna-205-5p (mir-205-5p) targeting high mobility group protein B1 / toll like receptor 4 (HMGB1 / TLR4) pathway on immune function of allergic rhinitis (AR). Methods: 60 male rats were selected and divided into normal control group (group A), allergic rhinitis group (group B), allergic rhinitis + miR-205-5p agomir group (group C), allergic rhinitis + miR-205- 5p antagomir group (group D) included 4 groups of 15 animals in each group. Group A did not receive any treatment, while groups B, C, and D were sensitized with ovalbumin nasal enhancement to establish AR models. After the model was established, 300 μg miR-205-5p agomir was injected into the tail of group C, miR-205-5p antagomir was injected into the tail of group D, and normal saline was injected into both groups A and B. One week later, the behavioral and immune-related indexes of each group [interferon-γ (IFN-γ), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-10 (IL-10), Immunoglobulin E (IgE)], nasal mucosal inflammatory response, tight junctions between epithelial cells, endoplasmic reticulum morphology and expression of tight junction proteins, HMGB1/TLR4 pathway proteins. The targeting relationship between miR-205-5p and TLR4 was analyzed using a dual-luciferase reporter assay. Results: The behavioral score, IL-4, IgE, HMGB1, TLR4, NF-κB expression and tight junction width of each group from low to high were group A < group B < group C < group D; IFN-γ, IL-2 The expression levels of IL-10, IL-10 and tight junction protein from low to high were group D < group C < group B < group A, and the differences between groups were statistically significant (all P < 0.05). The dual-luciferase reporter results indicated that miR-205-5p could target TLR4.Conclusion: miR-205-5p can target the HMGB1/TLR4 pathway to inhibit the AR immune disorder caused by Th1/Th2 imbalance, strengthen the barrier function of the nasal mucosa, thereby reducing the invasion of allergens, relieving AR-related symptoms, and having a positive effect on the treatment of AR .